Quantitative examination of the inhibitory activation of molecular targeting agents in hepatocellular carcinoma patient‐derived cell invasion via a novel in vivo tumor model

BACKGROUND: The outcomes for patients with advanced hepatocellular carcinoma (HCC) receiving sorafenib are far from satisfactory because of treatment resistance to sorafenib. However, the exact mechanism of resistance to sorafenib remains unclear and it is valuable to establish a novel mouse model t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Huiwei, Feng, Fan, Xie, Hui, Li, Xiaojuan, Jiang, Qiyu, Chai, Yantao, Wang, Zhijie, Yang, Ruichuang, Li, Ruisheng, Hou, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930997/
https://www.ncbi.nlm.nih.gov/pubmed/31942558
http://dx.doi.org/10.1002/ame2.12085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930997/
https://www.ncbi.nlm.nih.gov/pubmed/31942558
http://dx.doi.org/10.1002/ame2.12085

Ejemplares similares